Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2011, Article ID 810207, 6 pages doi:10.1093/ecam/nen040

Original Article

Antidiabetic Indian Plants: A Good Source of Potent Amylase Inhibitors

Menakshi Bhat,¹ Smita S. Zinjarde,¹ Shobha Y. Bhargava,² Ameeta Ravi Kumar,¹ and Bimba N. Joshi¹

¹ Institute of Bioinformatics and Biotechnology, University of Pune, Pune 411 007, India

Correspondence should be addressed to Bimba N. Joshi, bimba@unipune.ernet.in

Received 21 April 2007; Accepted 11 April 2008

Copyright © 2011 Menakshi Bhat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diabetes is known as a multifactorial disease. The treatment of diabetes (Type II) is complicated due to the inherent pathophysiological factors related to this disease. One of the complications of diabetes is post-prandial hyperglycemia (PPHG). Glucosidase inhibitors, particularly α -amylase inhibitors are a class of compounds that helps in managing PPHG. Six ethnobotanically known plants having antidiabetic property namely, *Azadirachta indica* Adr. Juss.; *Murraya koenigii* (L.) Sprengel; *Ocimum tenuflorum* (L.) (syn: *Sanctum*); *Syzygium cumini* (L.) Skeels (syn: *Eugenia jambolana*); *Linum usitatissimum* (L.) and *Bougainvillea spectabilis* were tested for their ability to inhibit glucosidase activity. The chloroform, methanol and aqueous extracts were prepared sequentially from either leaves or seeds of these plants. It was observed that the chloroform extract of *O. tenuflorum*; *B. spectabilis*; *M. koenigii* and *S. cumini* have significant α -amylase inhibitory property. Plants extracts were further tested against murine pancreatic, liver and small intestinal crude enzyme preparations for glucosidase inhibitory activity. The three extracts of *O. tenuflorum* and chloroform extract of *M. koenigi* showed good inhibition of murine pancreatic and intestinal glucosidases as compared with acarbose, a known glucosidase inhibitor.

1. Introduction

Diabetes is defined as a state in which homeostasis of carbohydrate and lipid metabolism is improperly regulated by the pancreatic hormone, insulin; resulting in an increased blood glucose level. Diabetes is a progressive disease and is one of the major killers in recent times. World Health Organization (WHO) suggests that worldwide the global population is in the midst of a diabetes epidemic with people in Southeast Asia and Western Pacific being mostly at risk. The number of cases for diabetes that is currently at 171 million is predicted to reach 366 million by the year 2030 [1].

Most prevalent form of diabetes is non-insulin dependent diabetes mellitus (NIDDM/type II). The treatment of type II diabetes is complicated by several factors inherent to the disease and elevated post prandial hyperglycemia (PPHG) is one of the risk factors [2]. PPHG is elevated by the action of glucosidases, a class of enzymes that helps in the breakdown of complex carbohydrates into simple sugars such as maltose and glucose. Glucosidase inhibitors such as α -amylase inhibitors plays a major role in managing PPHG

in diabetic patients. These α -amylase inhibitors inhibit the action of α -amylase enzyme leading to a reduction in starch hydrolysis which shows beneficial effects on glycemic index control in diabetic patients [3]. The known glucosidase inhibitors which are conventionally used in the management of diabetes are acarbose and miglitol (a deoxy nojirimycin derivative) that competitively and reversibly inhibits α -glucosidase enzyme from intestine as well as pancreas, however, both these drugs are known to be associated with gastrointestinal side effects such as abdominal pain, flatulence and diarrhea in the patients [4, 5]. Therefore, it becomes necessary to identify the amylase inhibitors from natural sources having lesser side-effects.

Ayurveda, the traditional Indian herbal medicinal system practiced for over thousands of years have reports of antidiabetic plants with no known side effects. Such plants and their products have been widely prescribed for diabetic treatment all around the world with less known mechanistic basis of their functioning. Hence, these natural products need to be evaluated scientifically and methodically in order to check for their properties [6, 7].

² Department of Zoology, University of Pune, Pune 411 007, India

We tested six plants namely Azadirachta indica; Syzy-gium cumini; Ocimum tenuflorum; Murraya koenigii; Linum usitatissimum traditionally used in Ayurveda along with Bougainvillea spectabilis used as a hypoglycemic plant in West Indies and some parts of Asia. Most of the plants tested in this study are part of dietary component, so there is less possibility of side effects caused by these plants. Of the six plants tested, A. indica and S. cumini are earlier reported to possess α -amylase inhibitory activity [8]. The extracts of all these plants were tested for their ability to inhibit the enzymatic activity of commercially available porcine pancreatic α -amylase and glucosidases from pancreas, liver and small intestine of Swiss mice.

2. Materials and Methods

- 2.1. Chemicals. DNSA (dinitrosalicylic acid), porcine pancreatic α -amylase and chloroform were obtained from SRL Pvt. Ltd (Mumbai, India). Di-potassium hydrogen phosphate (K_2HPO_4), potassium dihydrogen phosphate (K_1PO_4), methanol, sodium potassium tartarate, sodium hydroxide (NaOH), were obtained from Merck Chemicals Ltd (Mumbai, India). Sodium chloride (NaCl) was obtained from HiMedia Laboratories (Mumbai, India). Acarbose was obtained from Bayer Pharmaceuticals Pvt. Ltd (Mumbai, India). All the chemicals and reagents procured were of A.R. grade.
- 2.2. Plant Materials. Leaves of A. indica, M. koenigii, O. tenuflorum, B. spectabilis and seeds of L. usitatissimum and S. cumini were collected in and around Pune city in the months of February, March and June. All the plants were authenticated by Botanical Survey of India (BSI), Pune, India.
- 2.3. Preparation of Plant Extracts. The leaves were washed and air dried at room temperature. The chloroform, methanol and aqueous extracts were prepared sequentially in soxhlet extractor using 30 g of dried plant tissue mixed with 150 ml of the respective solvent (100% v/v) for 24 h [9, 10]. Methanolic and chloroform extracts were evaporated to dryness in rotary evaporator, whereas the aqueous extracts were lyophilized [11]. 25 mg dry weight of each crude extract was further reconstituted in 2.5 ml of distilled water and 1:20 dilution of all these extracts were used for further studies.
- 2.4. Preparation of Murine Pancreatic, Liver and Small Intestine Extracts. The 10-week-old Swiss male mice were procured from the animal house of Department of Zoology. The entire procedure was carried out with guidelines of Institutional Animal Ethical Committee. The mouse weighing 27 g was starved for 12 h. Pancreas; liver and small intestine tissues were excised and homogenized with 10 mM ice cold phosphate buffer containing 100 mM NaCl (1:10 dilution; w/v) and appropriate amount of protease inhibitors. The homogenate was centrifuged for 10 min at 10 000 r.p.m. and the supernatant was taken as a source of the enzyme [12].

- 2.5. α-Amylase Inhibition Assay. The 45.5 μg ml $^{-1}$ of porcine pancreatic α-amylase was incubated with 25 mg ml $^{-1}$ plant extracts. One percent starch was used as substrate. The plant extracts without α-amylase were used as controls and the test reading were subtracted from the absorbance of these controls. The reducing sugar was estimated using DNSA assay at A₅₄₀ nm and the enzyme units were expressed as micro molar per minute [13]. One unit of enzyme was defined as the amount of enzyme required to liberate 1 μM of maltose under assay conditions. The final inhibition shown by different crude extracts were compared with the standard inhibitor, 1.9 mM acarbose. The 50% inhibition concentration (IC₅₀) of plant extracts against porcine pancreatic α-amylase was also calculated.
- 2.6. Glucosidase Inhibition Assay with Murine Pancreatic, Liver and Small Intestinal Extracts. Supernatant obtained from pancreas, liver and small intestine tissues were taken as a source of enzyme and were diluted so as to get an absorbance of 0.4 (at 280 nm) which corresponds to 11.52, 3.62, and 46.40 μ g of protein respectively. Protein was estimated using Bradford standard curve [14]. The enzyme inhibition assay was carried out as described above. The 50% inhibition concentration (IC50) of plant extracts against pancreatic, small intestinal and liver glucosidases was calculated.
- 2.7. Statistical Analysis. The statistical analysis was performed using one way analysis of variance (ANOVA) and two tailed t-test (P < .05). Results are expressed as means \pm SEM n = 3.

3. Results

- 3.1. Porcine Pancreatic α -Amylase Inhibitory Activity of Plant Extracts. Porcine pancreatic α -amylase with 0.21 U min⁻¹ was taken as 100% enzymatic activity. Chloroform extract of *M. koenigii*, *B. spectabilis*, *O. tenuflorum* and *S. cumini* showed enzyme inhibition of 56.64, 29.43, 24.57 and 22.31% respectively (Figure 1). A significant inhibition was observed with extracts of *O. tenuflorum*; whereas *A. indica* and *L. usitatissimum* showed no inhibition with pure porcine α -amylase. The chloroform extract of *M. koenigii* showed significant difference with P < .05 as compared with other plant extracts (Figure 1).
- 3.2. Murine Pancreatic Glucosidases Inhibitory Activity of Plant Extracts. Murine pancreatic tissue weighing 1.2 g with 72.0 μ g ml⁻¹ of total protein was used as a source of enzyme, of which 11.5 μ g of protein was used for inhibition assay. Pancreatic enzyme activity exhibiting 0.26 U min⁻¹ was taken as 100% enzymatic activity. Chloroform extracts of M. koenigii, B. spectabilis and S. cumini showed enzyme inhibitory activity of 83.94, 51.99 and 43.28% and aqueous extracts of O. tenuflorum, L. usitatissimum and B. spectabilis showed enzyme inhibitory activity of 76.27, 61.68 and 55.32%, respectively as compared to acarbose which showed 40.43% enzyme inhibition. The plant extracts of A. indica




FIGURE 1: The percent relative enzyme activity after inhibition with (a) M. koenigii (b) B. spectabilis (c) O. tenuflorum (d) S. cumini, extracts on porcine pancreatic α -amylase. Acarbose is taken as standard α -amylase inhibitor. Pure porcine pancreatic α -amylase serves as control. The data is indicated as the mean \pm SEM; (n = 3). Data with different asterisks (*, ***, ****) shows significant difference with (*) denoting more significant value (P < .05), two-tailed student t-test.

and *L. usitatissimum* showed negligible enzyme inhibition. The chloroform extract of *O. tenuflorum* showed significant difference with P < .05 as compared with other plant extracts (Table 1).

3.3. Murine Small Intestinal Glucosidases Inhibitory Activity of Plant Extracts. Murine small intestine tissue weighing 0.6 g with $145 \,\mu \mathrm{g} \,\mathrm{ml}^{-1}$ total protein was used as a source of enzyme of which $46.40 \,\mu \mathrm{g}$ of protein was used for inhibition assay. Intestinal enzyme activity exhibiting 0.03 U min⁻¹ was taken as 100% enzymatic activity. Aqueous and methanolic extracts of *A. indica* showed enzyme inhibition of 62.44 and 41.07% while *M. koenigii* chloroform extract showed enzyme inhibition of 60.99 and 43.72%, respectively, followed by *S. cumini* chloroform extracts with 44.40% enzyme inhibition. However, acarbose failed to show any inhibition with intestinal glucosidase. The chloroform extract of *M. koenigii* showed significant difference with P < .05 as compared with other plant extracts (Table 2).

3.4. Murine Liver Glucosidases Inhibitory Activity of Plant Extracts. Murine liver tissue extract weighing 1.8 g with $181 \,\mu \mathrm{g} \,\mathrm{ml}^{-1}$ total protein was used as a source of enzyme, of which 3.62 $\,\mu \mathrm{g}$ of protein was used for inhibition assay. Liver enzyme activity exhibiting 0.06 U min⁻¹ was taken as 100% enzymatic activity. The methanolic extract of *S. cumini*, *A.*

Table 1: Percent enzyme inhibition shown by plant extracts with pancreatic glucosidases.

Acarbose (40.43 ± 1.22)	% Glucosidases inhibition activity			
	Methanol	Aqueous	Chloroform	
Murraya koenigii (L.) Sprengel	ND	ND	83.93 ± 1.55*	
Bougainvillea spectabilis	ND	55.31 ± 5.09	51.98 ± 6.07	
Ocimum tenuiflorum (L.)	ND	76.27 ± 3.67**	ND	
Syzygium cumini (L.) Skeels	ND	ND	43.28 ± 1.48	
Azadirachta indica Adr. Juss	ND	ND	ND	
Linum usitatissimum (L.)	26.01 ± 3.18	61.67 ± 2.86**	ND	

The table shows percent inhibition of pancreatic glucosidases using plant extracts. The data is indicated as the mean \pm SEM; (n=3). Two-tailed t-test was applied. Values with different asterisk (*, ***) shows significant difference with (*) denoting more significant value, P < .05, two-tailed student t-test. ND defines no enzyme inhibition.

indica and B. spectabilis showed inhibition of 55.09, 52.11 and 33.09% respectively, whereas the aqueous extracts of

TABLE 2: Percent enzyme inhibition shown by plant extracts with small intestinal glucosidases.

Acarbose (ND)	% Glucosidases inhibition activity		
	Methanol	Aqueous	Chloroform
Murraya koenigii (L.) Sprengel	43.71 ± 2.42	ND	60.99 ± 3.20**
Bougainvillea spectabilis	ND	ND	ND
Ocimum tenuiflorum (L.)	ND	ND	ND
Syzygium cumini (L.) Skeels	ND	ND	44.37 ± 1.92*
Azadirachta indica Adr. Juss	41.7 ± 2.97**	62.43 ± 3.35*	ND
Linum usitatissimum (L.)	ND	ND	ND

The table shows percent inhibitory activity of small intestinal glucosidases using plant extracts. The data is indicated as the mean \pm SEM; (n=3). Two-tailed t-test was applied. Values with different asterisks (*,**) shows significant difference with (*) denoting more significant value, P < .05, two-tailed student t-test. ND defines no enzyme inhibition.

Table 3: Percent enzyme inhibition shown by plant extracts with liver glucosidases.

Acarbose (95.61 ± 2.36)	(%) Glucosidases inhibition activity			
	Methanol	Aqueous	Chloroform	
Murraya koenigii (L.) Sprengel	ND	ND	ND	
Bougainvillea spectabilis	33.09 ± 3.02	ND	ND	
Ocimum tenuiflorum (L.)	ND	26.65 ± 3.98	ND	
Syzygium cumini (L.) Skeels	55.08 ± 3.32**	ND	ND	
Azadirachta indica Adr. Juss	52.10 ± 3.31**	69.28 ± 2.59*	ND	
Linum usitatissimum (L.)	ND	ND	ND	

The table shows percent inhibitory activity of liver glucosidases using plant extracts. The data is indicated as the mean \pm SEM; (n=3). Two-tailed t-test was applied. Values with different asterisks (*, **) shows significant difference with (*) denoting more significant value, P < .05, two-tailed student t-test. ND defines no enzyme inhibition.

A. indica and *O. tenuflorum* showed enzyme inhibition of 69.29 and 26.63%, respectively. The chloroform extract of *B. spectabilis* showed significant difference with P < .05 as compared with other plant extracts (Table 3).

4. Discussion

There are many reports of herbal extracts being used in Ayurvedic literature as antidiabetic which are directly or indirectly used for the preparation of many modern drugs. However, these plants have not gained much importance as medicines and one of the factors is lack of specific standards being prescribed for herbal medicines and supportive animal/clinical trials [15]. In the present study, we investigate six known plants, namely A. indica; S. cumini; O. tenuflorum; M. koenigii; L. usitatissimum and B. spectabilis having antidiabetic properties for their possible glucosidase inhibitory activity. Plants are known to produce a large variety of glucosidase inhibitors that provides protection against insects and microbial pathogens [16, 17] therefore plant extracts were analyzed for α -amylase inhibitory activity.

Pancreatic and intestinal glucosidases are the key enzymes of dietary carbohydrate digestion and inhibitors of these enzymes may be effective in retarding glucose absorption to suppress PPHG. In diabetic state, excessive hepatic glycogenolysis and gluconeogenesis is associated with decreased utilization of glucose by tissues being the fundamental mechanism underlying hyperglycemia [18]. The liver glucosidase inhibitors, inhibits α -1,6-glucosidase of glycogen-debranching enzymes in the liver and reduces the glycogenolytic rate which increases the accumulation of glycogen stores in the liver [19, 20]. Inhibition of these enzyme systems decreases the current blood glucose levels in diabetic patient (as a short term effect) and shows a small reduction in hemoglobin $_{\rm Alc}$ level (as a long term effect) [21].

Earlier studies indicated that M. koenigii possess hypoglycemic activity, decreased glycogenolysis and gluconeogenesis properties and also finds its application as an adjuvant to dietary therapy and drug treatment for controlling Diabetes Mellitus [22–24]. Our investigation reported M. koenigii as a good glucosidases inhibitor showing inhibition against porcine pancreatic α -amylase as well as murine pancreatic and intestinal glucosidases. The chloroform extract of M. koenigii showed significant inhibition (IC50 values of 1.96, 1.06 and 2.68 μ g ml⁻¹) with porcine pancreatic α -amylase (56.40%) as well as murine pancreatic and intestinal glucosidases, respectively, which is significantly higher than acarbose. Interestingly the phenolic content of this extract was very low, so the inhibitory activity may be because of specific inhibitory compounds. Methanolic extract showed inhibition (IC₅₀ value of 1.96 µg ml⁻¹) only with murine intestinal glucosidase as shown in Table 2.

Similarly *O. tenuflorum* shows inhibition of α -amylase known to possess antidiabetic properties [25, 26]. The three extracts of *O. tenuflorum* shows inhibitory activity against porcine α -amylase, murine pancreatic and liver glucosidases. Chloroform extract possess more potent inhibitory activity (IC₅₀ value of 1.76 μ g ml⁻¹) with murine pancreatic glucosidases. The inhibitory activity of aqueous extract (IC₅₀ values of 1.55 and 9.86 μ g ml⁻¹) was observed with porcine α -amylase and with murine liver glucosidases, respectively, which is significantly more than acarbose.

Syzygium cumini is known to possess properties of normoglycemia and lowers blood glucose levels by improving oral glucose tolerance [27, 28]. Our study suggests S. cumini as a good inhibitor of glucosidases. Inhibitory activity of chloroform extract (IC $_{50}$ values of 4.28, 3.72 and 5.60 μ g ml $^{-1}$) was observed against porcine α -amylase, murine pancreatic and murine intestinal glucosidases, respectively. The methanolic extract of S. cumini showed

inhibition with only murine liver glucosidases (IC₅₀ = $2.68 \mu g \text{ ml}^{-1}$).

Bougainvillea spectabilis on the other hand is being used for the treatment of diabetes in the islands of West Indies and Asia. It is claimed to exert insulin-like effects and contain D-pinitol (3-O-methylchiroinositol) [29–31]. Our studies indicated *B. spectabilis* chloroform extract has effective inhibition (IC₅₀ values of 3.20 and 2.06 μg ml⁻¹) on porcine pancreatic α-amylase and murine pancreatic glucosidases. The aqueous extract showed inhibition (IC₅₀ = 11.16 μg ml⁻¹) with murine pancreatic glucosidases and methanolic extract (IC₅₀ = 9.26 μg ml⁻¹) showed inhibition with murine liver glucosidase. The effects could be possibly because of the high-phenolic contents present in the crude extracts.

Azadirachta indica is one of the widely used antidiabetic plants, which possess hypolipidaemic, hypoglycaemic, immunostimulant and hepatoprotective properties [32–34]. Aqueous extracts of neem leaves was reported to reduce blood glucose and this effect could be due to blocking the action of epinephrine on glycogenolysis and peripheral utilization of glucose [35]. It is not a glucosidase inhibitor as evidenced by no significant inhibition with porcine pancreatic α-amylase. However, methanolic (IC₅₀ values of 2.60 and 1.80 μg ml⁻¹) and aqueous extract (IC₅₀ values of 3.17 and 6.21 μg ml⁻¹) showed inhibition with murine liver and intestinal glucosidases, respectively, which is significantly more than acarbose.

Linum usitatissimum is known to possess plasma triglycerides and cholesterol lowering properties. This plant being a dietary component is also known to have hypolipidemic effect [36]. We investigate its role as glucosidase inhibitor. The aqueous (IC₅₀ value of $3.21 \,\mu \mathrm{g} \,\mathrm{ml}^{-1}$) and methanolic extract (IC₅₀ value of $18.62 \,\mu \mathrm{g} \,\mathrm{ml}^{-1}$) has shown inhibition with murine pancreatic glucosidases which is significantly more than acarbose.

Diabetes being multifactorial disease the treatment choice differs from patient to patient. Therefore, it is important to find out the biological activity of these herbal extracts. Theoretically, these glucosidase inhibitors from plants act through a variety of mechanism. Presently it is not possible either to pin point the exact mechanism of inhibition of these extracts or to identify the active principle(s) responsible for such effect in this study. Nevertheless, the present study identifies the *M. koenigii* and *O. tenuflorum* as good glucosidase inhibitors of pancreatic and intestinal enzymes. They can be further studied and may be used as dietary supplement for controlling PPHG in type II diabetes.

5. Conclusion

M. koenigii and O. tenuflorum shows significant inhibition with porcine pancreatic, murine pancreatic as well as intestine glucosidase. This may have beneficial effects in managing type II diabetes mellitus and could be used as an indicator for combinational therapy which can be taken up in further studies.

Acknowledgments

Authors acknowledge Department of Zoology, University of Pune, India for providing infrastructure facilities. M.B. is thankful to Council of Scientific and Industrial Research (CSIR, Government of India) for providing Junior Research Fellowship. Authors also acknowledge financial support from CSIR, India.

References

- [1] World Health Organization (WHO), "Diabetes Programme," 2006, http://www.who.int/diabetes/en/.
- [2] H. Gin and V. Rigalleau, "Post-prandial hyperglycemia. Post-prandial hyperglycemia and diabetes," *Diabetes and Metabolism*, vol. 26, no. 4, pp. 265–272, 2000.
- [3] A. L. Notkins, "Immunologic and genetic factors in type 1 diabetes," *Journal of Biological Chemistry*, vol. 277, no. 46, pp. 43545–43548, 2002.
- [4] T. Fujisawa, H. Ikegami, K. Inoue, Y. Kawabata, and T. Ogihara, "Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms," *Metabolism*, vol. 54, pp. 387–390, 2005.
- [5] S. K. Singh, P. K. Rai, D. Jaiswal, and G. Watal, "Evidence-based critical evaluation of glycemic potential of Cynodon dactylon," *Evidence-Based Complementary and Alternative Medicine*, vol. 6, no. 4, pp. 415–420, 2007.
- [6] B. Patwardhan, A. D. B. Vaidya, and M. Chorghade, "Ayurveda and natural products drug discovery," *Current Science*, vol. 86, no. 6, pp. 789–799, 2004.
- [7] O. Said, S. Fulder, K. Khalil, H. Azaizeh, E. Kassis, and B. Saad, "Maintaining a physiological blood glucose level with 'glucolevel', a combination of four anti-diabetes plants used in the traditional Arab herbal medicine," *Evidence-Based Complementary and Alternative Medicine*, vol. 5, no. 4, pp. 421–428, 2008.
- [8] M. I. Kotowaroo, M. F. Mahomoodally, A. Gurib-Fakim, and A. H. Subratty, "Screening of traditional antidiabetic medicinal plants of Mauritius for possible α-amylase inhibitory effects in vitro," Phytotherapy Research, vol. 20, no. 3, pp. 228– 231, 2006.
- [9] S. A. Adesegun, A. Fajana, C. I. Orabueze, and H. A. B. Coker, "Evaluation of antioxidant properties of *Phaulopsis fascisepala* C.B.Cl. (Acanthaceae)," *Evidence-Based Complementary and Alternative Medicine*, vol. 6, no. 2, pp. 227–231, 2007.
- [10] I. S. R. Punitha, K. Rajendran, A. Shirwaikar, and A. Shirwaikar, "Alcoholic stem extract of Coscinium fenestratum regulates carbohydrate metabolism and improves antioxidant status in streptozotocin-nicotinamide induced diabetic rats," Evidence-Based Complementary and Alternative Medicine, vol. 2, no. 3, pp. 375–381, 2005.
- [11] G. Tafesse, Y. Mekonnen, and E. Makonnen, "Antifertility effect of aqueous and ethanol extracts of the leaves and roots of Asparagus africanus in rats," *African Health Sciences*, vol. 6, no. 2, pp. 81–85, 2006.
- [12] G. Ersoz, A. Huseyinov, O. Ozutemiz, G. Yuce, I. Coker, and Y. Batur, "Leukotrienes in cerulein-induced acute pancreatitis in rats and effect of octreotide," *Turkish Journal of Gastroenterology*, vol. 10, no. 1, pp. 40–47, 1999.
- [13] G. L. Miller, "Use of dinitrosalicylic acid reagent for determination of reducing sugar," *Analytical Chemistry*, vol. 31, pp. 426–428, 1959.

- [14] C. de Barros Pontes, A. C. Polizello, and A. C. Spadaro, "Clinical and biochemical evaluation of the saliva of patients with xerostomia induced by radiotherapy," *Pesquisa Odontológica Brasileira*, vol. 18, no. 1, pp. 69–74, 2004.
- [15] S. S. Gupta, "Prospects and perspectives of natural products in medicine," *Indian Journal of Pharmacology*, vol. 26, pp. 1–12, 1994.
- [16] C. Ryan, "Protease inhibitor gene families: strategies for transformation to improve plant defenses against herbivores," *BioEssays*, vol. 10, pp. 20–24, 1989.
- [17] S. Lu, P. Deng, X. Liu et al., "Solution structure of the major α-amylase inhibitor of the crop plant amaranth," *Journal of Biological Chemistry*, vol. 274, no. 29, pp. 20473–20478, 1999.
- [18] A. Latner, "Carbohydrate metabolism, abnormalities of post absorbtive blood sugar level," in *Clinical Biochemistry*, p. 48, WB. Saunders, Philadelphia, Pa, USA, 1958.
- [19] M. Bollen and W. Stalmans, "The antiglycogenolytic action of 1-deoxynojirimycin results from a specific inhibition of the a-1, 6-glucosidase activity of the debranching enzyme," *European Journal of Biochemistry*, vol. 181, pp. 775–780, 1989.
- [20] Y. Yoshikuni, "Inhibition of intestinal a-glucosidase activity and postprandial hyperglycemia by moranoline and its Nalkyl derivatives," *Agricultural and Biological Chemistry*, vol. 52, pp. 121–128, 1988.
- [21] S. J. Venable and D. S. Aschenbrenner, "Drug Therapy in Nursing," Lippincott Williams & Wilkins, Hagerstwon, MD, USA, 2005.
- [22] B. A. Khan, A. Abraham, and S. Leelamma, "Biochemical response in rats to the addition of curry leaf (Murraya koenigii) and mustard seeds (Brassica juncea) to the diet," *Plant Foods for Human Nutrition*, vol. 49, no. 4, pp. 295–299, 1996.
- [23] P. Arulselvan, G. P. Senthilkumar, D. S. Kumar, and S. Subramanian, "Anti-diabetic effect of Murraya koenigii leaves on streptozotocin induced diabetic rats," *Pharmazie*, vol. 61, no. 10, pp. 874–877, 2006.
- [24] A. N. Kesari, R. K. Gupta, and G. Watal, "Hypoglycemic effects of Murraya koenigii on normal and alloxan-diabetic rabbits," *Journal of Ethnopharmacology*, vol. 97, no. 2, pp. 247–251, 2005.
- [25] V. Vats, S. P. Yadav, and J. K. Grover, "Cholinergic basis of memory improving effect of *Ocimum tenuflorum* linn," *Journal of Ethnopharmacology*, vol. 68, pp. 90–155, 2004.
- [26] R. R. Chattopadhyay, "Hypoglycemic effect of Ocimum sanctum leaf extract in normal and streptozotocin diabetic rats," *Indian Journal of Experimental Biology*, vol. 31, no. 11, pp. 891– 893, 1993.
- [27] K. Ravi, D. Sathish Sekar, and S. Subramanian, "Hypoglycemic activity of inorganic constituents in Eugenia jambolana seed on streptozotocin-induced diabetes in rats," *Biological Trace Element Research*, vol. 99, no. 1–3, pp. 145–155, 2004.
- [28] M. Pandey and A. Khan, "Hypoglycaemic effect of defatted seeds and water soluble fibre from the seeds of *Syzygium cumini* (Linn.) skeels in alloxan diabetic rats," *Indian Journal of Experimental Biology*, vol. 40, no. 10, pp. 1178–1182, 2002.
- [29] C. R. Narayanan, D. D. Joshi, A. M. Mujumdar, and V. V. Dhekne, "Pinitol, a new antidiabetic compound from the leaves of *Bougainvillea spectabilis*," *Current Science*, vol. 56, pp. 139–141, 1987.
- [30] C. R. Narayanan, D. D. Joshi, and A. M. Mujumdar, "Hypoglycemic action of *Bougainvillea spectabilis* leaves," *Current Science*, vol. 53, pp. 579–581, 1984.
- [31] J. O. Adebayo, A. A. Adesokan, L. A. Olatunji, D. O. Buoro, and A. O. Soladoye, "Effect of ethanolic extract of *Bougainvillea*

- spectabilis leaves on haematological and serum lipid variables in rats," *Biochemistry*, vol. 17, pp. 45–50, 2005.
- [32] K. N. Bopana, J. Kannan, S. Gadgil, R. Balaram, and S. P. Rathod, "Antidiabetic and antihyperlipidaemic effects of neem seed kernel powder on alloxan diabetic rabbits," *Indian Journal of Pharmacology*, vol. 29, pp. 162–167, 1997.
- [33] P. Khosla, S. Bhanwara, J. Singh, S. Seth, and R. K. Srivastava, "A study of hyperglycemia effects of *A. indica* (Neem) in normal and alloxan diabetic rabbits," *Indian Journal of Pharmacology*, vol. 44, pp. 69–74, 2000.
- [34] P. Sen, P. K. Mediratta, and A. Ray, "Effects of Azadirachta indica A Juss on some biochemical, immunological and visceral parameters in normal and stressed rats," *Indian Journal of Experimental Biology*, vol. 30, no. 12, pp. 1170–1175, 1992.
- [35] R. R. Chattopadhyay, R. N. Chattopadhyay, and S. K. Maitra, "Effect of *A. indica* on hepatic glycogen in rats," *Indian Journal of Pharmacology*, vol. 25, pp. 174–175, 1993.
- [36] S. J. Bhathena, A. A. Ali, C. Haudenschild et al., "Dietary flaxseed meal is more protective than soy protein concentrate against hypertriglyceridemia and steatosis of the liver in an animal model of obesity," *Journal of the American College of Nutrition*, vol. 22, no. 2, pp. 157–164, 2003.